Inozyme Pharma, Inc. (INZY) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 6 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for INZY is $4.00, representing a +0.0% upside from the current price of $4. Price targets range from a low of $4.00 to a high of $4.00.
